| Literature DB >> 26338462 |
Yuqing Wang1, Chuangli Hao1, FanFan Chi1, Xingmei Yu1, Huiquan Sun1, Li Huang1, Meijuan Wang1, Wei Ji1, Yongdong Yan1, Hong Zhu2, Xuejun Shao2.
Abstract
Protracted bacterial bronchitis (PBB) is the common cause of chronic cough in children worldwide, but its etiology has not been fully recognized in China. We retrospectively investigated a total of 66 hospitalized infants under the age of three years with chronic wet cough enrolled in the Affiliated Children's Hospital of Soochow University from October 2010 to March 2014. All patients underwent bronchoscopy and broncho-alveolar lavage (BAL) samples were processed for microbiological and cytological analysis. Of 66 patients with wet cough, 50 (75.8%) were diagnosed with PBB. In the PBB group, wet cough was accompanied by wheezing (90%). Airway malacia were identified in 22 cases (44%). The clinical manifestations of PBB with airway malacia did not differ from those without malacia. Haemophilus influenzae (47.4%) and Streptococcus pneumoniae (36.8%) were the most commonly identified pathogens. Furthermore, CD3(+) and CD3(+)CD4(+) cells were significantly lower in the PBB group (p < 0.01), while CD19(+), CD16(+)CD56(+) and CD23(+) cells were elevated (p < 0.01) in the PBB group. Our study revealed PBB is an important cause of chronic wet cough in Chinese infants, and that changes of lymphocyte subsets are observed in children with PBB. Airway malacia frequently co-existed with PBB, but did not exacerbate the disease.Entities:
Mesh:
Year: 2015 PMID: 26338462 PMCID: PMC4559899 DOI: 10.1038/srep13731
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics and clinical features of patients with PBB and no PBB controls.
| Characteristics | PBB group (n = 50), (%) | No PBB group (n = 16), (%) | p |
|---|---|---|---|
| mean age [months] | 10.00 (5.75–14) | 12 (7–18.5) | >0.05 |
| gender | |||
| male | 43 (86) | 12 (75) | >0.05 |
| female | 7 (14) | 4 (25) | >0.05 |
| symptoms | |||
| wet cough | 50 (100) | 16 (100) | >0.05 |
| wheezing | 45 (90) | 10 (62.5) | <0.01*** |
| stridor | 2 (4) | 1 (6.25) | >0.05 |
| phase of cough | |||
| morning | 8 (16) | 4 (25) | >0.05 |
| night | 8 (16) | 4 (25) | >0.05 |
| both day and night | 32 (64) | 7 (43.8) | <0.05* |
| post-activity | 2 (4) | 1 (6.25) | >0.05 |
| median duration of cough [weeks] | 10.0 ± 16.4 | 15.1 ± 1 6.3 | >0.05 |
| physical examination | |||
| wheezing rales | 41 (82) | 11 (68.7) | >0.05 |
| moist rales | 23 (46) | 9 (56.2) | >0.05 |
P-values < 0.05* and <0.01*** were considered statistically significant.
Figure 1Bronchoscopic findings of a patient with PBB.
Redness and edema of the bronchial mucous membranes accompanied by bronchomalacia are seen under bronchoscopy.
Demographic and clinical features in PBB with or without airway deformity.
| Characteristics | no airway deformity (n = 28), n (%) | airway deformity (n = 22) n (%) | p |
|---|---|---|---|
| mean age [months] | 12 (7.25–16.75) | 8 (5–10) | <0.05* |
| gender | |||
| male | 23 (82.1) | 20 (90.9) | >0.05 |
| female | 5 (17.9) | 2 (9.1) | >0.05 |
| symptom | |||
| cough | 28 (100) | 22 (100) | >0.05 |
| wheezing | 23 (82.1) | 20 (90.9) | >0.05 |
| stridor | 0 (0) | 2 (28.6) | <0.05* |
| phase of cough | |||
| in the morning | 6 (21.4) | 2 (9.1) | >0.05 |
| at night | 5 (17.9) | 3 (13.6) | >0.05 |
| both day and night | 17 (60.7) | 15 (68.2) | >0.05 |
| post-activity | 0 (0) | 2 (9.1) | >0.05 |
| median duration of cough [days] | 9.1 ± 13.7 | 11.3 ± 19.6 | >0.05 |
| physical examination | |||
| lung wheezing rales | 23 (82.1) | 18 (79.6 ) | >0.05 |
| lung moist rales | 11 (39.2) | 12 (9.3) | >0.05 |
| cellularity of BALF | |||
| neutrophil (%) | 26.0 ± 32.15 | 33.3 ± 27.6 | >0.05 |
| lymphocyte (%) | 7.2 ± 6.4 | 9.1 ± 6.6 | >0.05 |
| macrophage (%) | 64.2 ± 34.2 | 56.9 ± 31.0 | >0.05 |
| eosinophil (%) | 2.6 ± 13.2 | 0.60 ± 2.0 | >0.05 |
| positive bacterial cultures of BALF | 11 (39.3) | 8 (36.4) | >0.05 |
| Streptococcus pneumoniae | 5 (17.9) | 4 (18.2) | >0.05 |
| Haemophilus influenzae | 5 (17.9) | 1 (4.5) | >0.05 |
| E. coli | 1 (3.6) | 1 (4.5) | >0.05 |
| Andenteroaerogen | 0 (0) | 1 (4.5) | >0.05 |
| Filamentous fungi | 0 (0) | 1 (4.5) | >0.05 |
| immunoglobulins (g/l) | |||
| IgA | 0.3 ± 0.3 | 0.3 ± 0.3 | >0.05 |
| IgG | 5.4 ± 2.0 | 6.0 ± 2.6 | >0.05 |
| IgM | 1.2 ± 0.6 | 0.9 ± 0.4 | >0.05 |
| lymphocyte subsets (%) | |||
| CD3+ | 60.0 ± 10.7 | 58.3 ± 13.5 | >0.05 |
| CD3+CD4+ | 35.1 ± 9.1 | 34.2 ± 12.5 | >0.05 |
| CD4+CD8+ | 22.0 ± 7.6 | 21.9 ± 7.6 | >0.05 |
| CD3−CD19+ | 29.1 ± 10.9 | 26.8 ± 11.4 | >0.05 |
| CD3−CD16+CD56+ | 9.0 ± 6.3 | 12.9 ± 9.1 | >0.05 |
| CD19+CD23+ | 14.0 ± 6.3 | 13.6 ± 6.1 | >0.05 |
P-values < 0.05* were considered statistically significant.
BALF cytology and immune function of patients with PBB and controls.
| Characteristics | PBB group (n = 50), n (%) | No PBB group (n = 16), n (%) | p |
|---|---|---|---|
| cellularity of BALF | |||
| neutrophil (%) | 29.2 ± 30.2 | 2.9 ± 3.5 | <0.01** |
| lymphocyte (%) | 8.1 ± 6.5 | 8.4 ± 4.3 | >0.05 |
| macrophage (%) | 61.0 ± 32.7 | 88.7 ± 3.6 | <0.01** |
| eosinophil (%) | 1.7 ± 9.9 | 0.00 ± 0.00 | >0.05 |
| positive bacterial cultures of BALF | 19 (38) | 0 (0) | <0.05* |
| airway deformity | 22 (44) | 10 (62.5) | >0.05 |
| immunoglobulins (g/L) | |||
| IgA | 0.3 ± 0.3 | 0.5 ± 0.6 | >0.05 |
| IgG | 5.65 ± 2.3 | 6.0 ± 2.2 | >0.05 |
| IgM | 1.1 ± 0.6 | 1.2 ± 0.7 | >0.05 |
| lymphocyte subsets (%) | |||
| CD3+ | 59.3 ± 11.9 | 68.6 ± 4.25 | <0.01** |
| CD3+CD4+ | 34.7 ± 10.6 | 42.5 ± 6.8 | <0.01** |
| CD4+CD8+ | 1.9 ± 1.3 | 2.1 ± 1.0 | >0.05 |
| CD3−CD19+ | 28.1 ± 11.1 | 23.2 ± 5.05 | <0.05* |
| CD3−CD16+CD56+ | 10.75 ± 7.8 | 7.45 ± 3.7 | <0.05* |
| CD19+CD23+ | 13.9 ± 6.2 | 5.4 ± 2.65 | <0.01** |
P-values < 0.05*, <0.01** were considered statistically significant.
Associations between lymphocyte subsets and cough severity in PBB patients.
| Characteristic | VCD scores ≥3 (n = 25) | VCD scores 1~2 (n = 21) | VCD scores 0 ~1 (n = 4) | p |
|---|---|---|---|---|
| lymphocyte subsets (%) | ||||
| CD3+ | 58.55 ± 12.95 | 62.37 ± 12.69 | 65.10 ± 12.30 | >0.05 |
| CD3+CD4+ | 35.28 ± 11.18 | 38.98 ± 12.87 | 31.80 ± 2.54 | >0.05 |
| CD4+CD8+ | 20.63 ± 5.44 | 20.70 ± 9.57 | 31.60 ± 13.15 | >0.05 |
| CD3−CD19+ | 28.71 ± 12.22 | 26.89 ± 13.63 | 19.40 ± 20.51 | >0.05 |
| CD3−CD16+CD56+ | 11.01 ± 6.24 | 8.74 ± 8.47 | 14.10 ± 8.49 | >0.05 |
| CD19+CD23+ | 13.41 ± 5.57 | 12.51 ± 7.76 | 14.00 ± 16.97 | >0.05 |
VCD, verbal category descriptive.
Associations between lymphocyte subsets and cough duration in PBB patients.
| Characteristic | 4-8 weeks (n = 33) | 8-12 weeks (n = 8) | ≥12 weeks (n = 9) | p |
|---|---|---|---|---|
| lymphocyte subsets (%) | ||||
| CD3+ | 60.15 ± 11.82 | 57.20 ± 3.25 | 60.83 ± 6.99 | >0.05 |
| CD3+CD4+ | 35.26 ± 10.14 | 33.30 ± 4.24 | 35.03 ± 5.65 | >0.05 |
| CD4+CD8+ | 21.73 ± 8.38 | 21.80 ± 0.28 | 23.45 ± 4.99 | >0.05 |
| CD3−CD19+ | 29.44 ± 11.43 | 21.60 ± 10.47 | 31.35 ± 9.34 | >0.05 |
| CD3−CD16+CD56+ | 8.69 ± 5.73 | 19.50 ± 7.07 | 5.65 ± 3.82 | >0.05 |
| CD19+CD23+ | 13.71 ± 6.56 | 11.45 ± 0.50 | 17.10 ± 6.30 | >0.05 |